1. Home
  2. ORC vs OMER Comparison

ORC vs OMER Comparison

Compare ORC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORC
  • OMER
  • Stock Information
  • Founded
  • ORC 2010
  • OMER 1994
  • Country
  • ORC United States
  • OMER United States
  • Employees
  • ORC N/A
  • OMER N/A
  • Industry
  • ORC Real Estate Investment Trusts
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORC Real Estate
  • OMER Health Care
  • Exchange
  • ORC Nasdaq
  • OMER Nasdaq
  • Market Cap
  • ORC 660.1M
  • OMER 188.1M
  • IPO Year
  • ORC 2013
  • OMER 2009
  • Fundamental
  • Price
  • ORC $7.15
  • OMER $3.65
  • Analyst Decision
  • ORC Hold
  • OMER Strong Buy
  • Analyst Count
  • ORC 3
  • OMER 5
  • Target Price
  • ORC N/A
  • OMER $18.00
  • AVG Volume (30 Days)
  • ORC 3.8M
  • OMER 928.7K
  • Earning Date
  • ORC 07-24-2025
  • OMER 08-06-2025
  • Dividend Yield
  • ORC 20.14%
  • OMER N/A
  • EPS Growth
  • ORC N/A
  • OMER N/A
  • EPS
  • ORC 0.46
  • OMER N/A
  • Revenue
  • ORC $52,240,000.00
  • OMER N/A
  • Revenue This Year
  • ORC $46.17
  • OMER N/A
  • Revenue Next Year
  • ORC $26.45
  • OMER $468.75
  • P/E Ratio
  • ORC $15.59
  • OMER N/A
  • Revenue Growth
  • ORC N/A
  • OMER N/A
  • 52 Week Low
  • ORC $5.69
  • OMER $2.95
  • 52 Week High
  • ORC $9.01
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • ORC 53.78
  • OMER 54.74
  • Support Level
  • ORC $7.10
  • OMER $3.00
  • Resistance Level
  • ORC $7.28
  • OMER $3.25
  • Average True Range (ATR)
  • ORC 0.11
  • OMER 0.24
  • MACD
  • ORC 0.02
  • OMER 0.10
  • Stochastic Oscillator
  • ORC 70.65
  • OMER 83.33

About ORC Orchid Island Capital Inc.

Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: